HIMS Earnings: Hims & Hers Stock Falls 10% as Financial Results Miss Wall Street Targets

Hims & Hers reported Q1 revenue of $608 million, below the $616.8 million consensus, and EPS of -$0.40 versus an expected profit of $0.03. The company also lifted full-year revenue guidance to $2.8 billion-$3.0 billion from $2.7 billion-$2.9 billion, though Q2 revenue guidance of $2.8 billion-$3.0 billion was only modestly above the $2.7 billion consensus. Shares fell as much as 10% after hours amid the earnings miss and ongoing scrutiny tied to its prior Wegovy copycat product and related lawsuit.

Analysis

The market is likely treating this as more than an earnings miss; it is repricing the durability of the business model. The key second-order issue is that HIMS has been forced to swap a high-margin, semi-proprietary compounding/replication economics stream for a lower-margin branded distribution model, which compresses unit economics even if top-line optics hold up. That means the real risk is not one quarter of earnings volatility, but a step-down in long-run contribution margin and a higher regulatory discount rate on future growth.

Near term, the stock can remain fragile because the next catalyst path is asymmetric: any follow-up guidance cut, margin pressure from mix shift, or regulatory commentary will matter more than incremental revenue beats over the next 1-2 quarters. The after-hours drawdown also signals that positioning was likely still growth-premium heavy; de-rating can continue if investors conclude the addressable market is intact but monetization is less scalable. For NVO, the relationship is mildly positive operationally because enforcement and distribution control reduce channel leakage, but the benefit is small relative to the reputational and legal overhang created by the episode.

The contrarian view is that the market may be over-penalizing the company’s ability to rebuild growth with better compliance and a more credible product set. If management can prove the branded GLP-1 relationship drives retention rather than just substitution, the multiple could stabilize within 2-3 quarters. But until there is evidence that gross margin and CAC payback are not structurally impaired, this looks like a story stock transitioning into a fundamentals stock — usually a painful rerating process.

Key Decisions for Investors

• Short HIMS into any relief rally over the next 1-3 weeks; risk/reward favors fading strength until the market sees a clean read-through on margin durability and regulatory normalization.
• Use put spreads on HIMS with 1-2 month tenor to express downside without unlimited theta bleed; target a move toward prior support if analysts revise estimates lower after the print.
• Pair trade: short HIMS / long NVO for 1-3 months. The thesis is that NVO captures incremental control over GLP-1 distribution while HIMS absorbs the valuation and execution penalty from the disruption.
• If you want to express a contrarian rebound, wait for a second-quarter operating update rather than buying the first dip; only go long after evidence that revenue re-acceleration is accompanied by stable gross margin and guidance credibility.
• For event-driven accounts, consider a small tactical short with a hard stop above the post-earnings gap if the stock reclaims the pre-announcement level; the upside is capped by de-rating, while downside extends if analysts cut price targets aggressively.